The LDN Books

We would like to thank all the authors for their time and support with The LDN Books, as well as the staff at Chelsea Green Publishing.  Generously, all royalties will be given to the LDN Research Trust. 

Low Dose Naltrexone (LDN) holds the potential to help millions of people suffering from various autoimmune diseases and cancers, and even those with autism, chronic fatigue, and depression find relief. Administered off-label in small daily doses (0.5 to 4.5 mg), this generic drug is extremely affordable and presents few known side effects. So why has it languished in relative medical obscurity?

The LDN Books explain the drug’s origins, its primary mechanism, and the latest research from practicing physicians and pharmacists as compiled by Linda Elsegood of The LDN Research Trust, the world’s largest LDN charity organization with over 19,000 members worldwide. Featuring ten chapters contributed by medical professionals on LDN’s efficacy and two patient-friendly appendices, The LDN Books are a comprehensive resource for doctors, pharmacists, and patients who want to learn more about how LDN is helping people now; and a clarion call for further research that could help millions more.

Checking the details of The LDN Book Volume 2

Details of the LDN Book Volume 2 Launch and Tour

Praise for The LDN Book Volume 1

Dr. Chris Steele, MBE, general practitioner; medical presenter on ITV’s This Morning

“I first came across LDN several years ago when a medical colleague said I should look into its positive effects in patients with MS, Crohn’s disease, and other autoimmune disorders. I was so impressed with what I read that I helped submit a petition to the UK government to ask for funding for further research into this inexpensive drug. But, as with so many petitions, no progress was made. I hope The LDN Book—which presents up-to-date findings that again confirm the efficacy of this safe, cheap, generic drug in helping to control many chronic, disabling conditions—is read by those in the Department of Health and by all doctors caring for patients with autoimmune disease. In the UK, LDN has been stranded in limbo; maybe now the time has come for it to be accepted as a recognized therapy that could, at least, be tried on those suffering such long-term diseases of the immune system.”

New Review The LDN Book - Jacqueline Young

Jackie is the Patron of the LDN Research Trust

“Low Dose Naltrexone (LDN) was discovered by my husband and partner, Dr. Bernard Bihari. Incredibly informative and superbly written by various members of the medical profession sharing their experiences using this extraordinary drug, The LDN Book honors his legacy in helping patients suffering from autoimmune and other diseases to regain their health and their lives.”

The LDN Book review by Dr Thomas Cowan

“As a practicing physician who has used LDN as a cornerstone therapy for over fifteen years, I can say without equivocation that LDN is the most important and successful medicine I have ever used. I often joke that if not for LDN I couldn’t pay my mortgage; I’ve had so many new patients referred to me by someone whose life has improved dramatically through the use of LDN. And despite my knowledge and experience with LDN, I’ve learned a great deal from The LDN Book—aspects of its basic science I hadn’t known, new uses, and how its uses can inform us about the causes of various diseases. This is a wonderful book for any patient with an autoimmune disease, cancer, depression, or a host of other conditions and is a must-read for any physician whose goal is to help their patients.”

— Dr. Thomas Cowan, author of The Fourfold Path to Healing and co-author of The Nourishing Traditions Book of Baby & Child Care

Introduction to The LDN Book Volume 1  - Click Here

Are you a Medical Professional? Would you like to sell The LDN Books?   Contact Us

Chelsea Green Publishing offers wholesale discounts to those in the USA; other countries please Contact Us

  • 5-9 Books - 45% Discount
  • 10 Books - 50% Discount
  • 25 Books -  50% and Free Shipping in the USA